Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemoimmunotherapy in stage III-IVA cervical cancer
IRCT20261022071515N1Phase 2Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Cervical Cancer (CC), sponsored by Tehran University of Medical Sciences. Primary endpoint: Clinical response rate. Started Nov 2026; status: recruiting.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on IRCT20261022071515N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20261022071515N1.